1RXSJ062518.2+733433: A new intermediate polar

We report the identification of the cataclysmic variable 1RXSJ062518.2+733433 as an intermediate polar. The orbital period of the system is determined to be 283.0+-2 min from the radial velocity variation of Halpha, measured in an extensive set of time-resolved spectroscopy. Differential optical photometry obtained over a base line of three weeks reveals the presence of coherent variability with a period of 19.788+-0.002 min, which we suggest to be the white dwarf spin period. The power spectrum of our photometry also contains a strong signal near the spectroscopically determined orbital period. The emission lines in 1RXSJ062518.2+733433 display a complex multicomponent structure. In the trailed spectrogram of HeI 6678 we detect a narrow component with a radial velocity semi-amplitude of ~140kms, consistent with a possible origin on the irradiated face of the secondary. The absence of eclipses gives an upper limit on the binary inclination of i<=60deg.Comment: 7 pages, A&A-Latex, 9 Figures, accepted for publication in A&

Prevalence and potential relevance of hyperuricemia in pediatric kidney transplant recipients—a CERTAIN registry analysis

Background: Asymptomatic hyperuricemia is frequently observed in pediatric kidney transplant recipients; symptomatic hyperuricemia, however, is a rare complication. Only few data are available in this patient population. We, therefore, investigated the prevalence of hyperuricemia and its association with kidney transplant function and blood pressure in a multicenter cohort of pediatric kidney transplant recipients. Methods: This is a retrospective, observational multicenter registry study. All pediatric kidney transplant recipients in the CERTAIN database with at least one documented serum uric acid level and a follow-up of 5 years posttransplant were eligible. We identified 151 patients with 395 measurements of serum uric acid. We calculated the prevalence of hyperuricemia, analyzed potential risk factors and clinical consequences such as elevated blood pressure and reduced estimated glomerular filtration rate (eGFR). Statistical analysis was performed using IBM SPSS Statistics 26. Results: One hundred and ten of 395 (27.8%) serum uric acid levels were above 416 µmol/L (7.0 mg/dL), defined as the upper limit of normal. Univariate analysis showed a significant (p = .026) inverse association of serum uric acid with eGFR overtime. There was no significant association of serum uric acid concentrations with body mass index (z-score), blood pressure (z-score), or sex. No episodes of gout were documented. Conclusion: This study shows that hyperuricemia is present in a considerable number of patients sometime after pediatric kidney transplantation and is associated with lower eGFR. Whether hyperuricemia contributes to faster decline of graft function or to the overall cardiovascular risk of these patients remains to be elucidated. Keywords: gout; long-term outcome; pediatric kidney transplantation; uric acid; uric acid-lowering therapy

Dwarf novae in the Hamburg quasar survey : rarer than expected

Aims. We report the discovery of five new dwarf novae that were spectroscopically identified in the Hamburg Quasar Survey (HQS),and discuss the properties of the sample of new dwarf novae from the HQS. Methods. Follow-up time-resolved spectroscopy and photometry have been obtained to characterise the new systems. Results. The orbital periods determined from analyses of the radial velocity variations and/or orbital photometric variability are Porb 105.1min or Porb 109.9min for HS 0417+7445, Porb = 114.3 ± 2.7min for HS 1016+3412, Porb = 92.66 ± 0.17 min for HS 1340+1524, Porb = 272.317 ± 0.001 min for HS 1857+7127, and Porb = 258.02 ± 0.56 min for HS 2214+2845. HS 1857+7127 is found to be partially eclipsing. In HS 2214+2845 the secondary star of spectral type M3 ± 1 is clearly detected, and we estimate the distance to the system to be d = 390 ± 40 pc. We recorded one superoutburst of HS 0417+7445, identifying the system as a SUUMatype dwarf nova. HS 1016+3412 and HS 1340+1524 have rare outbursts, and their subtype is yet undetermined. HS 1857+7127 frequently varies in brightness and may be a ZCam-type dwarf nova. HS 2214+2845 is a UGem-type dwarf nova with a most likely cycle length of 71 d. Conclusions. To date, 14 new dwarf novae have been identified in the HQS. The ratio of short-period (3 h)systems of this sample is 1.3, much smaller compared to the ratio of 2.7 found for all known dwarf novae. The HQS dwarf novae display typically infrequent or low-amplitude outburst activity, underlining the strength of spectroscopic selection in identifying new CVs independently of their variability. The spectroscopic properties of short-period CVs in the HQS, newly identified and previously known, suggest that most, or possibly all of them are still evolving towards the minimum period. Their total number agrees with the predictions of population models within an order of magnitude. However, the bulk of all CVs is predicted to have evolved past the minimum period, and those systems remain unidentified. This suggests that those post-bounce systems have markedly weaker Hβ emission lines compared to the average known short-period CVs, and undergo no or extremely rare outbursts

Unterschiedliche Genexpression in metastasierenden und nicht metastasierenden Endometriumkarzinomen

Genetische Faktoren, die Tumore befähigen Metastasen zu bilden, sind nur unzureichend bekannt. Ausgehend von der Frage, ob sich metastasierende und nicht-metastasierende Endometriumkarzinome in der Genexpression unterscheiden, konnten drei Kandidatengene mittels Differential Display-Technik identifiziert werden. In einem größeren Kollektiv bestätigte sich zudem eine Assoziation zur Überlebenszeit. Die Genfragmente zeigten jeweils Homologien zu bekannten Gensequenzen auf Chromosom 16, Chromosom 22 und Chromosom 20. Der auf Chromosom 20 lokalisierte Abschnitt kodiert für das hypothetische Protein KIAA 1434. Dieses ist sehr wahrscheinlich in den Energiestoffwechsel der Zelle involviert. Um eine funktionelle Aussage über KIAA 1434 treffen zu können, sind jedoch weitere Untersuchungen notwendig

Cardiovascular Risk and Mineral Bone Disorder in Patients with Chronic Kidney Disease

The term chronic kidney disease-mineral bone disorder has been coined recently to highlight that the disturbed mineral and bone metabolism is a major contributor to vascular calcification and finally cardiovascular disease. This syndrome is characterized by clinical, biochemical and/or histological findings, i.e. i) biochemical alterations in the homeostasis of calcium, phosphate and their key player parathyroid hormone (PTH), Fibroblast growth factor-23 (FGF-23), klotho and vitamin-D, ii) the occurrence of vascular and/or soft tissue calcification, and iii) an abnormal bone structure and/or turnover. Apart from the combined and synergistic action of "traditional" and uremia-related risk factors, promoters and inhibitors of calcification have to be considered as well. This review will focus on the disturbed mineral metabolism as the triggering force behind distortion of vascular integrity and cardiovascular malfunction in CKD patients

Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease

<div><p>Monitoring metabolic adaptation to chronic kidney disease (CKD) early in the time course of the disease is challenging. As a non-invasive technique, analysis of exhaled breath profiles is especially attractive in children. Up to now, no reports on breath profiles in this patient cohort are available. 116 pediatric subjects suffering from mild-to-moderate CKD (n = 48) or having a functional renal transplant KTx (n = 8) and healthy controls (n = 60) matched for age and sex were investigated. Non-invasive quantitative analysis of exhaled breath profiles by means of a highly sensitive online mass spectrometric technique (PTR-ToF) was used. CKD stage, the underlying renal disease (HUS; glomerular diseases; abnormalities of kidney and urinary tract or polycystic kidney disease) and the presence of a functional renal transplant were considered as classifiers. Exhaled volatile organic compound (VOC) patterns differed between CKD/ KTx patients and healthy children. Amounts of ammonia, ethanol, isoprene, pentanal and heptanal were higher in patients compared to healthy controls (556, 146, 70.5, 9.3, and 5.4 ppbV vs. 284, 82.4, 49.6, 5.30, and 2.78 ppbV). Methylamine concentrations were lower in the patient group (6.5 vs 10.1 ppbV). These concentration differences were most pronounced in HUS and kidney transplanted patients. When patients were grouped with respect to degree of renal failure these differences could still be detected. Ammonia accumulated already in CKD stage 1, whereas alterations of isoprene (linked to cholesterol metabolism), pentanal and heptanal (linked to oxidative stress) concentrations were detectable in the breath of patients with CKD stage 2 to 4. Only weak associations between serum creatinine and exhaled VOCs were noted. Non-invasive breath testing may help to understand basic mechanisms and metabolic adaptation accompanying progression of CKD. Our results support the current notion that metabolic adaptation occurs early during the time course of CKD.</p></div

Clinical characteristics of patients.

<p>Data is given as median and range. Superscripts denote significant differences between identically labelled groups.</p

Exhaled alveolar concentrations of isoprene relative to the BMI in controls (blue circles) and patients (red circles).

<p>Controls (n = 60): r = 0.53, p < 0.001; patients (n = 56): r = 0.47, p<0.001.</p

Anthropometric data of the study population and relevant medications in CKD patients.

<p>Anthropometric data of the study population and relevant medications in CKD patients.</p